A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

NCT06990399 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema Secondary to Inflammation

Interventions

DRUG: KSI-101
OTHER: Sham Comparator

Sponsor

Kodiak Sciences Inc